ARMATA PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $11.65 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.61, a 469.12% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.04, a 39.64% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.38, a 43.22% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.36.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.04, a 38.92% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.34, a 39.75% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.39, a 51.72% decline from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.95, a 3.77% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $11.65 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $11.61 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $2.04 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $2.04 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $2.04 10-Q · filed 2025-08-12 | ||||
| 2025-03-31 | $2.04 10-Q · filed 2025-05-14 | ||||
| 2024-12-31 | $3.34 10-K · filed 2025-03-21 | ||||
| 2024-09-30 | $3.38 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $3.38 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $3.38 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | $2.39 10-K · filed 2024-03-21 | ||||
| 2023-09-30 | $2.36 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $2.36 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $2.36 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $4.95 10-K · filed 2023-03-16 | ||||
| 2022-09-30 | $5.04 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $5.08 10-Q · filed 2022-08-11 | ||||
| 2021-12-31 | $4.77 10-K · filed 2022-03-17 | ||||
| 2021-09-30 | $4.77 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $4.96 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $5.14 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $3.38 10-K · filed 2021-03-18 | ||||
| 2020-09-30 | $3.57 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $3.55 10-Q · filed 2020-08-13 | ||||
| 2020-03-31 | $3.85 10-Q · filed 2020-05-14 | ||||
| 2019-12-31 | $3.18 10-K · filed 2020-03-19 | ||||
| 2019-09-30 | $3.17 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $3.15 10-Q · filed 2019-08-14 | ||||
| 2018-12-31 | $1.18 10-K · filed 2019-03-25 | ||||
| 2018-09-30 | $1.20 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $1.20 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $1.23 10-Q · filed 2018-05-15 | ||||
| 2017-12-31 | $1.22 10-K · filed 2019-03-25 | ||||
| 2017-09-30 | $1.22 10-Q · filed 2017-11-14 | ||||
| 2017-06-30 | $2.29 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | $4.50 10-Q · filed 2017-05-15 | ||||
| 2016-12-31 | $26.48 10-K · filed 2018-03-14 | $2.65 10-K · filed 2017-03-27 | |||
| 2016-09-30 | $2.82 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $2.85 10-Q · filed 2016-08-15 | ||||
| 2016-03-31 | $2.83 10-Q · filed 2016-05-12 | ||||
| 2015-12-31 | $8.47 10-K · filed 2016-03-30 | ||||
| 2015-09-30 | $8.72 10-Q · filed 2016-11-10 | $8.72 10-Q · filed 2016-11-10 | |||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |